SANTA
CLARA, Calif., May 1, 2023
/PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company
that provides technology solutions to improve the clinical
effectiveness and efficiency of healthcare providers, today
announced that it will report financial results for the first
quarter ended March 31, 2023, after
the close of U.S. financial markets on Wednesday, May 10, 2023. Doug Murphy-Chutorian, M.D., interim chief
executive officer of Semler Scientific, will host a conference call
at 4:30 pm ET the same day.
Andrew Weinstein, senior vice
president, finance and accounting, Dennis
Rosenberg, chief marketing officer, and Renae Cormier, head of corporate communications
and business strategy, will join him on the call.
We encourage participants to pre-register for the conference
call using the following link:
https://dpregister.com/sreg/10177436/f8f3c160f0. Callers
who pre-register will be given a conference passcode and unique PIN
to gain immediate access to the call and bypass the live operator.
Participants may pre-register at any time, including up to and
after the call start time.
Those without internet access or unable to pre-register may dial
in by calling:
Domestic callers: 866-777-2509
International callers: 412-317-5413
Please specify to the operator that you would like to join the
"Semler Scientific Call." The conference call will be archived on
Semler Scientific's website at www.semlerscientific.com.
About Semler Scientific, Inc.:
Semler Scientific,
Inc. develops, manufactures and markets innovative products and
services that assist in evaluating and treating chronic
diseases. Its flagship product, QuantaFlo®, which is patented
and cleared by the U.S. Food and Drug Administration (FDA), is a
rapid point-of-care test that measures arterial blood flow in the
extremities. The QuantaFlo® test aids in the diagnosis of
cardiovascular diseases, such as peripheral arterial disease (PAD)
and heart dysfunction (HD). QuantaFlo® is used by healthcare
providers to evaluate their patient's risk of mortality and major
adverse cardiovascular events (MACE). In addition, Semler
Scientific has an agreement with Mellitus Health, Inc. (Mellitus)
to exclusively market and distribute Insulin Insights™, an
FDA cleared software product that recommends optimal insulin dosing
for diabetic patients in the United
States, including Puerto
Rico. Semler Scientific has a minority investment in
Mellitus, as well as Monarch Medical Technologies LLC, a privately
held company whose product EndoTool® offers a technological
solution for inpatient glycemic management. Additional information
about Semler Scientific can be found at
www.semlerscientific.com.
CONTACT:
Susan A.
Noonan
S.A. Noonan Communications
susan@sanoonan.com
917 513 5303
View original content to download
multimedia:https://www.prnewswire.com/news-releases/semler-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-10-2023-301812180.html
SOURCE Semler Scientific, Inc.